Search the Newsreel

ROUNDUP: Energiekontor im ersten Halbjahr mit Verlust - Prognose aber bestätigt - 13.08.26 - News

Anel Elektrik yönetim kurulundan sürdürülebilirlik komitesi kararı

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Brokerages

Nektar Therapeutics (NASDAQ:NKTR) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $150.00. The company's shares opened at $75.50, and institutional investors own 75.88% of the stock. Insider selling has also been noted, with executives selling …

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

Kuehn Law is investigating Nektar Therapeutics (NASDAQ: NKTR) following a federal securities lawsuit alleging that the company misrepresented or failed to disclose issues with its REZOLVE-AA trial for its lead product candidate. The lawsuit claims that enrollment did not follow protocol standards, which was …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NKTR) on behalf of investors who purchased securities before February 26, 2025, and still hold them. The investigation aims to determine if Nektar's officers and/or directors engaged in corporate wrongdoing. The firm …

Lawsuit alleges Nektar Therapeutics misled investors on clinical trial integrity.

Kuehn Law is investigating Nektar Therapeutics over allegations that the company misled shareholders regarding the integrity of its REZOLVE-AA clinical trial. The lawsuit claims Nektar Therapeutics failed to adhere to trial protocols, overstated the trial's validity, and made false public statements. This could negatively …

KAREL ELEKTRONIK - KAP Haberleri - 2026-08-10 tarihli

Nektar Therapeutics $NKTR Shares Sold by Renaissance Technologies LLC

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR). The investigation concerns whether Nektar and certain officers engaged in corporate wrongdoing. Investors who purchased Nektar securities prior to February 26, 2025, and continue to hold them, …

EMPAE Hisse Yorumları (EMPA ELEKTRONIK Güncel Yorumlar)

CCORF Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $153

CCORF has reiterated its Buy rating on Nektar Therapeutics (NKTR.US) and maintained its target price at $153. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

Is Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics (NKTR)?

Nektar Therapeutics has initiated two global Phase 3 trials, ZENITH AD‑1 and ZENITH AD‑2, for its drug rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. This development is seen as a crucial step for the company, potentially reshaping its investment narrative by providing a near-term …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …

Enterprise value to EBIT forward of Nektar Therapeutics – NASDAQ:NKTR

This article presents financial data for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its enterprise value to EBIT forward. The data is provided by TradingView, indicating that the market for NKTR was closed at the time of publication with no trades. The content highlights …

Vanguard Capital Management (NKTR) discloses 5.17% beneficial stake in Nektar

Vanguard Capital Management has reported a beneficial ownership of 5.17% in Nektar Therapeutics (NKTR) common stock as of June 30, 2026. This stake, totaling 1,747,653 shares, includes holdings in Vanguard funds and managed accounts. Vanguard exercises sole voting power over 250,804 shares and sole …

Nektar Therapeutics (NKTR) Expected to Post Quarterly Earnings on Thursday

Nektar Therapeutics $NKTR Shares Acquired by Swiss National Bank

JTEKT India Limited Releases Business Responsibility and Sustainability Report for FY 2025-26

BlackRock (NYSE: BLK) discloses 7.8% beneficial stake in Nektar Therapeutics (NKTR)

BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Nektar Therapeutics (NKTR), amounting to 2,643,796 shares of common stock as of June 30, 2026. This ownership was reported via a Schedule 13G filing, indicating that BlackRock holds sole voting power over 2,590,855 shares …

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics will announce its second-quarter financial results on Thursday, August 13, 2026, after the close of U.S.-based financial markets. President and CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. An audio-only webcast will …

Nektar CEO Will Review Second-Quarter Results in Aug. 13 Webcast

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026, after the close of U.S. financial markets. CEO Howard Robin will host a conference call at 5:00 p.m. ET / 2:00 p.m. …

Nektar Therapeutics Q2 Results: Earnings date set for Aug 13

Nektar Therapeutics (Nasdaq: NKTR) is scheduled to release its second-quarter 2026 financial results on August 13, 2026, after the U.S. markets close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results, the company's financial health, and advancements …

Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis

Nektar Therapeutics (NKTR) has a current financial score of 6.40, placing it 254th out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently reported a quarterly revenue of $10.86 million, a 3.83% year-over-year …

Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Nektar Therapeutics (NKTR), highlighting its current valuation score of 7.54, which ranks 213 out of 386 in its industry. It details the company's current P/E ratio of -9.01, noting its position relative to recent highs and lows. …

FORTEC Elektronik Aktiengesellschaft Appoints Yannick Moyles-Johnson to the Management Board and as New CFO

GERMERING, GERMANY - July 27, 2026 (NEWMEDIAWIRE) - The Supervisory Board of FORTEC Elektronik Aktiengesellschaft ("FORTEC"), a leading provider of solutions in the fields of display technology and power supplies, has appointed Mr. Yannick Moyles-Johnson as the Group's Chief Financial Officer. This implements the …

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Nektar Therapeutics (NKTR) has initiated Phase 3 trials for rezpegaldesleukin in atopic dermatitis, a move that follows significant one-year stock growth but also a recent pullback. Despite a narrative suggesting a 54% undervaluation based on future revenue potential, its current P/S ratio signals high …

Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Nektar Therapeutics' (NKTR) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also includes institutional shareholding data over several quarters and recent shareholder activity, highlighting changes in holdings by various investment …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing by its officers and/or directors. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …

Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Nektar Therapeutics (NKTR), noting a lack of detailed financial disclosures for recent fiscal years. It indicates that all reported revenue, totaling $55.23 million, comes from the "Rest of world" region, with no disclosed revenue from the United …

How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials

Nektar Therapeutics has initiated global Phase 3 trials (ZENITH AD-1 and AD-2) for rezpegaldesleukin in moderate-to-severe atopic dermatitis, building on positive Phase 2b data and FDA Fast Track status. This move positions the T-reg–targeting biologic as a central focus for Nektar's autoimmune franchise but …

Nektar Therapeutics (NKTR) Institutional Confidence

The article provides an overview of Nektar Therapeutics' (NKTR) institutional confidence score, which stands at 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding proportion is 61.39%, a 16.36% decline quarter-over-quarter. James Simons is the largest institutional shareholder, with other major …

Nektar Therapeutics (NKTR) awards 16,500 stock options to Chief R&D Officer

Nektar Therapeutics has granted Chief R&D Officer Jonathan Zalevsky 16,500 stock options with an exercise price of $15.1500 per share, expiring December 12, 2032. These options, issued under the 2017 Amended and Restated Performance Incentive Plan, are subject to both performance-based and time-based vesting. …

Form 4 Nektar Therapeutics For: 24 July By Investing.com

This article reports on a Form 4 filing for Nektar Therapeutics (NKTR) on July 24, indicating insider transactions. The brief piece includes the stock's performance on the day and is framed within a typical financial news portal layout with various market data and related …

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics announced the grant of non-qualified stock options to 23 newly-hired employees under its 2025 Inducement Plan, as permitted by Nasdaq Listing Rule 5635(c)(4). These options cover 36,000 shares of common stock at an exercise price of $64.84, vesting over four years. The …

CATES ELEKTRIK U - KAP Haberleri - 2026-07-24 tarihli